Combined serum miR-29c and miR-149 expression analysis as diagnostic genetic markers for colorectal cancer

Circulating miRNAs gathered much interest in cancer research as noninvasive biomarkers. The aim of this study was to analyze the expression of miR-29c and miR-149 among colorectal cancer (CRC) patients and to explore their diagnostic and prognostic potentials in relation to the clinical and pathological features. The expression levels of miR-29c and miR-149 were evaluated in the sera of 80 CRC patients, 80 colorectal adenoma (CRA) patients, and 80 healthy controls using quantitative real time polymerase chain reaction (PCR). Carcinoembryonic antigen serum levels were assayed using enzyme-linked immunosorbent assay. miR-29c and miR-149 were significantly downregulated among CRC patients compared with CRA and controls (miR-29c, 0.54 +/- 0.19 vs. 0.86 +/- 0.12, 0.99 +/- 0.07,P < 0.001, respectively; miR-149, 0.46 +/- 0.19 vs. 0.74 +/- 0.012, 1.0 +/- 0.22,P < 0.001, respectively). miR-29c and miR-149 significantly associated with advanced stages of CRC, tumor size, and lymphatic metastasis. By using receiver operating characteristic curve analysis, combined miR-29c and miR-149 revealed the highest diagnostic potential for CRA (area under the curve [AUC] = 0.967) from healthy controls as well as the diagnosis of CRC (AUC = 0.98) from CRA. Moreover, combined miRNAs revealed high diagnostic potential for the earlier stages of CRC compared with advanced stages (AUC = 0.96). In conclusion, combined serum miR-29c and miR-149 expression analysis established novel noninvasive biomarker for early CRC diagnosis.

Automated summary

Circulating miR-29c and miR-149 are significantly downregulated in CRC patients and associated with clinical features of the disease. Combined analysis of miR-29c and miR-149 represents a novel noninvasive biomarker for early diagnosis of CRC.